AstraZeneca (AZN)
(Delayed Data from NSDQ)
$78.54 USD
+0.36 (0.46%)
Updated May 24, 2024 04:00 PM ET
After-Market: $78.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AZN 78.54 +0.36(0.46%)
Will AZN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AZN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AZN
Pharma Stock Roundup: AZN's 2030 Sales Target, PFE's New Cost Cut Plan & More
Why Astrazeneca (AZN) is a Great Dividend Stock Right Now
AZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
Other News for AZN
Wall Street Breakfast: The Week Ahead
Week In Review: Hengrui And Dearon Announce $7.2B In Drug Licensings
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
AstraZeneca’s Growth Trajectory: A Buy Rating Justified by Strong Pipeline and Revenue Targets
AstraZeneca price target raised by 500 GBp at Morgan Stanley